胱抑素C与20年听力损失累积发病率的关联:听力损失流行病学研究
基于Beaver Dam地区听力损失流行病学研究,纳入863名基线无听力损失的48-86岁参与者,随访20年。结果显示,以胱抑素C估算的肾功能降低(eGFRCysC<60 vs ≥60 mL/min/1.73 m2)与听力损失累积发病率显著相关(多变量校正HR 1.50, 95%CI 1.02-2.22),而胱抑素C浓度本身在多变量校正后关联减弱。
要点
- 胱抑素C估算的肾功能降低与20年听力损失累积发病率独立相关。
- 胱抑素C浓度单独在多变量校正后与听力损失关联不显著。
- 部分年龄相关听力损失可能与肾功能降低同时发生或由其导致。
核心结论
- 以胱抑素C估算的肾功能降低,而非胱抑素C单独,与20年听力损失累积发病率相关。
研究设计与样本
- 纵向人群研究,数据来自美国威斯康星州Beaver Dam的听力损失流行病学研究。
- 基线检查于1993-1995年进行,每约5年随访一次,最近一次检查于2015年完成。
- 纳入863名48-86岁、有血清胱抑素C数据且基线无听力损失的参与者。
主要发现
- 年龄和性别校正模型中,胱抑素C浓度每增加0.2 mg/L,听力损失风险HR为1.20(95%CI 1.07-1.34)。
- 进一步校正教育水平、当前吸烟、腰围和糖化血红蛋白后,HR为1.11(95%CI 0.98-1.27)。
- 低eGFRCysC(<60 vs ≥60 mL/min/1.73 m2)在年龄和性别校正模型中与听力损失累积发病率显著相关(HR 1.70, 95%CI 1.16-2.48)。
- 多变量校正模型中,低eGFRCysC与听力损失累积发病率仍显著相关(HR 1.50, 95%CI 1.02-2.22)。
关键数值与推荐
- 听力损失定义为任一耳0.5、1、2、4 kHz纯音平均听阈>25 dB HL。
- 胱抑素C作为生物标志物浓度分析,并用于计算估算肾小球滤过率(eGFRCysC)。
临床怎么用
- 在评估年龄相关听力损失风险时,可关注以胱抑素C估算的肾功能降低。
- 肾功能降低者可能需加强听力监测,但需进一步研究验证因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Hearing impairment (HI) is one of the most common conditions affecting older adults. Identification of factors associated with the development of HI may lead to ways to reduce the incidence of this condition. OBJECTIVE: To investigate the association between cystatin C, both as an independent biomarker and as a marker of kidney function, and the 20-year incidence of HI. DESIGN, SETTING, AND PARTICIPANTS: Data were obtained from the Epidemiology of Hearing Loss Study (EHLS), a longitudinal, population-based study in Beaver Dam, Wisconsin. Baseline examinations began in 1993 and continued through 1995, and participants were examined approximately every 5 years, with the most recent examination phase completed in 2015. The EHLS participants with serum cystatin C concentration data and without HI at the baseline examination were included in this study. MAIN OUTCOMES AND MEASURES: Participants without HI were followed up for incident HI (pure-tone average of hearing thresholds at 0.5, 1, 2, and 4 kHz >25 dB hearing level in either ear) for 20 years. Cystatin C was analyzed as a biomarker (concentration) and used to determine estimated glomerular filtration rate (eGFRCysC). Discrete-time Cox proportional hazards regression models were used to analyze the association between cystatin C concentration and eGFRCysC and the 20-year cumulative incidence of HI. RESULTS: There were 863 participants aged 48 to 86 years with cystatin C data and without HI at baseline. Of these, 599 (69.4%) were women. In models adjusted for age and sex, cystatin C was associated with an increased risk of developing HI (hazard ratio [HR], 1.20; 95% CI, 1.07-1.34 per 0.2-mg/L increase in cystatin C concentration), but the estimate was attenuated after further adjusting for educational level, current smoking, waist circumference, and glycated hemoglobin (HR, 1.11; 95% CI, 0.98-1.27 per 0.2-mg/L increase in cystatin C concentration). Low eGFRCysC was significantly associated with the 20-year cumulative incidence of HI in both the age- and sex-adjusted model (HR, 1.70; 95% CI, 1.16-2.48; <60 vs ≥60 mL/min/1.73 m2) and the multivariable-adjusted model (HR, 1.50; 95% CI, 1.02-2.22; <60 vs ≥60 mL/min/1.73 m2). CONCLUSIONS AND RELEVANCE: Reduced kidney function as estimated using cystatin C, but not cystatin C alone, was associated with the 20-year cumulative incidence of HI, suggesting that some age-related HI may occur in conjunction with or as the result of reduced kidney function.
引用
- Schubert CR, Paulsen AJ, Nondahl DM, et al. Association Between Cystatin C and 20-Year Cumulative Incidence of Hearing Impairment in the Epidemiology of Hearing Loss Study. JAMA Otolaryngol Head Neck Surg. 2018. PMID: 29710267. doi:10.1001/jamaoto.2018.0041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。